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and Laboratory Medicine. The meeting, which was held 
on September 16, 2010, aimed to develop a consensus 
statement on the adherence to two recently-released In-
formational Supplements to the Clinical and Laboratory 
Standards Institute (CLSI) Antimicrobial Susceptibility 
Guidelines (CLSI-2010 and CLSI-June 2010-update) for 
Enterobacteriaceae in clinical microbiology laboratories of 
Taiwanese hospitals.1–3
These two 2010 CLSI Informational Supplements in-
clude new (revised) interpretive criteria for several cepha-
losporins (cefazolin, cefotaxime, ceftriaxone, ceftizoxime), 
aztreonam, and carbapenems (ertapenem, imipenem, mero-
penem, and doripenem) for Enterobacteriaceae isolates using 
the disk diffusion method (Table 1) and minimum inhibitory 
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A consensus meeting was organized under the auspices of 
the Infectious Diseases Society of Taiwan, the Taiwan 
Society of Microbiology, the Taiwan Society of Laboratory 
Medicine, and the Taiwan Society of Clinical Pathology 
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concentrations (MIC) susceptibility testing (Tables 2 and 
3).1–3 These revised interpretive criteria were approved 
by the CLSI committee members after evaluation of the 
pharmacokinetic-pharmacodynamic properties of these 
agents, the distribution of MIC, and, unfortunately, limited 
data on clinical outcome.
For cephalosporins, the current CLSI Informational 
Supplements note that when using the new interpretive 
criteria, routine testing for extended-spectrum β-lactamases 
(ESBL) is no longer necessary before reporting results (e.g. 
it is no longer necessary to edit results for cephalo sporins, 
aztreonam, or penicillins from susceptible to resistant).1–2 
Table 2. Minimum inhibitory concentration interpretive breakpoints for several cephalosporins and aztreonam established in 
January 2009 and January 2010 by the Clinical and Laboratory Standards Institute and the minimum inhibitory concentration 
ranges tested in two commercial automated instrumentsa
 MIC interpretive breakpoints (μg/mL)
Agent CLSI 2009 (M100-S19) CLSI 2010 (M100-S20) 
MIC rangeb
 Susceptible Intermediate Resistant Susceptible Intermediate Resistant Vitek II Phoenix
Cefazolin ≤ 8 16 ≥ 32 ≤ 1 2 ≥ 4 4–64b 4–16b
Cefotaxime ≤ 8 16–32 ≥ 64 ≤ 1 2 ≥ 4 1–64 1–32
Ceftriaxone ≤ 8 16–32 ≥ 64 ≤ 1 2 ≥ 4 1–64 4–32b
Ceftizoxime ≤ 8 16–32 ≥ 64 ≤ 1 2 ≥ 4 1–64 –
Ceftazidime ≤ 8 16 ≥ 32 ≤ 4 8 ≥ 16 1–64 0.5–16
Cefepime        
Aztreonam ≤ 8 16 ≥ 32 ≤ 4 8 ≥ 16 1–64 2–16
aInformation from references 1 and 2; bthe MIC ranges are not able to detect susceptible or intermediate isolates when using new CLSI-2010 
interpretive MIC breakpoints (M100-S20). MIC = minimum inhibitory concentration; CLSI = Clinical and Laboratory Standards Institute.
Table 1. Interpretive zone diameter breakpoints for disk diffusion susceptibility testing for several cephalosporins, aztreonam, 
and carbapenems established in January 2009 and January 2010 by the Clinical and Laboratory Standards Institutea
  Interpretive zone diameter breakpoints (mm)
Antimicrobial agent CLSI document
 Susceptible Intermediate Resistant
Cefotaxime or ceftriaxone M100-S20 (2010) ≥ 26 23–25 ≤ 22
  ≥ 23 20–22 ≤ 19
 M100-S19 (2009) ≥ 21 14–20 ≤ 13
Ceftazidime M100-S20 (2010) ≥ 21 18–20 ≤ 17
 M100-S19 (2009) ≥ 18 15–17 ≤ 14
Ceftizoxime M100-S20 (2010) ≥ 25 22–24 ≤ 21
 M100-S19 (2009) ≥ 20 15–19 ≤ 14
Aztreonam M100-S20 (2010) ≥ 21 18–20 ≤ 17
 M100-S19 (2009) ≥ 22 16–21 ≤ 15
Doripenem M100-S20-U (2010-June) ≥ 23 20–22 ≤ 19
Ertapenem M100-S20-U (2010-June) ≥ 23 20–22 ≤ 19
 M100-S20 (2010) ≥ 19 16–18 ≤ 15
Imipenem/Meropenem M100-S20-U (2010-June) ≥ 23 20–22 ≤ 19
 M100-S20 (2010) ≥ 16 14–15 ≤ 13
aInformation from references 1 and 2. CLSI = Clinical and Laboratory Standards Institute.
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ESBL testing may still be useful for epide miological or 
infection control purposes, and should still be performed 
until the new interpretive criteria are implemented.1–2 
These informational supplements did not change the in-
terpretive criteria for cefepime and cefuroxime (paren-
teral).1–2 They also emphasize that interpretive criteria for 
drugs with limited availability in many countries (i.e. moxa-
lactam, cefonicid, cefamandole, and cefoperazone) were 
not evaluated.2 If considering use of these drugs in treat-
ing patients with infections due to Escherichia coli, Klebsiella, 
or Proteus spp. isolates, ESBL testing should be performed. 
If the isolates exhibited an ESBL-producing phenotype, 
the results for moxalactam, cefonicid, cefamandole, and 
cefoperazone should be considered as resistant.2
The rationale for setting new interpretive breakpoints 
for carbapenems is the presence of carbapenamases in 
Enterobacteriaceae that are largely responsible for MICs 
and zone diameters in the new intermediate and resistant 
ranges.3 Implementation of the new breakpoints can ob-
viate the need for screening or confirmatory testing for 
Klebsiella pneumoniae carbapenamases (KPC) by the modi-
fied Hodge test (MHT).3 Once laboratories implement 
these new interpretive criteria, MHT does not need to be 
performed other than for epidemiology and infection 
control purposes.3
The consensus meeting agreed that there is no need to 
apply the revised interpretive criteria for cephalosporins 
and carbapenems to define susceptibility categories for 
Enterobacteriaceae for several reasons. First, the new ceftazi-
dime (≤ 4 μg/mL) and the unchanged cefepime (≤ 8 μg/mL) 
susceptible breakpoints failed to identify many ESBL-
producing E. coli, K. pneumoniae, and K. oxytoca (Figure).4–5 
Indications for the clinical use of cefepime or third-
generation cephalosporins for the treatment of infections 
caused by ESBL-producing E. coli and K. pneumoniae iso-
lates with lower MICs (≤ 8 μg/mL for cefepime and ≤ 4 μg/
mL for ceftazidime) remain unclear.2 Similarly, the clini-
cal efficacy of carbapenems for the treatment of infec-
tions caused by isolates for which the carbapenem MIC or 
Table 3. Minimum inhibitory concentration interpretive breakpoints for carbapenems established in January 2010 and June 2010 
by the Clinical and Laboratory Standards Institute and the minimum inhibitory concentration ranges tested in two commercial 
automated instrumentsa
 MIC interpretive breakpoints (μg/mL)
Agent CLSI 2010 (M100-S20) CLSI 2010-Update (M100-S20-U) 
MIC range (μg/mL)
 Susceptible Intermediate Resistant Susceptible Intermediate Resistant Vitek II Phoenix
Ertapenem ≤ 2 4 ≥ 8 ≤ 0.25 0.5 ≥ 1 0.5–8b 0.5–4b
Imipenem ≤ 4 8 ≥ 16 ≤ 1 2 ≥ 4 0.25–16 1–8
Meropenem ≤ 4 8 ≥ 16 ≤ 1 2 ≥ 4 0.25–16 1–8
Doripenem – – – ≤ 1 2 ≥ 4 0.12–8 –
aInformation from references 4 and 5; bthe MIC ranges are not able to detect susceptible or intermediate isolates when using the new CLSI-
2010 June interpretive MIC breakpoints (M100-S20-U). MIC = minimum inhibitory concentration; CLSI = Clinical and Laboratory Standards 
Institute.
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Figure. Susceptibility rates to ceftriaxone, ceftazidime and 
cefepime for extended-spectrum β-lactamase-producing Escherichia 
coli, Klebsiella pneumoniae and K. oxytoca isolates retrieved from 
SMART (Study for Monitoring Antimicrobial Resistance Trends) 
data from the Asia-Pacific region (2008) and worldwide (2007–9). 
The data were analyzed based on the new 2010 CLSI MIC inter-
pretive breakpoints for Enterobacteriaceae (M00-S20). Adapted 
from reference 3.
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disk diffusion test results are within the new intermediate 
range remains uncertain due to the lack of controlled 
clinical studies.3 In Taiwan, ertapenem is widely used for 
the treatment of infections due to ESBL-producing and 
multidrug-resistant Enterobacteriaceae. Interestingly, an ad-
ditional 12% of ESBL-producing K. pneumoniae isolates were 
not susceptible to ertapenem (90–78%) and an additional 
27% of Enterobacter cloacae isolates were not susceptible to 
ertapenem (96–69%) when the new MIC interpretive break-
points for carbapenems were applied compared with the 
old criteria [unpublished data from Study for Monitoring 
Antimicrobial Resistance Trends (SMART)-2009]. The 
majority of clinical microbiology laboratories in Taiwan 
routinely perform screening and confirmatory testing for 
Enterobacteriaceae isolates. Clinicians in Taiwan are famil-
iar with the need for routine reporting of ESBL isolates 
and all are well trained to prescribe an appropriate and 
recommended agent (a carbapenem) for the treatment of 
patients with these infections. Furthermore, some agents, 
including moxalactam, flomoxef and cefoperazone, are 
still available in the formulary in many Taiwanese hos-
pitals and are routinely included in susceptibility testing 
in clinical microbiology laboratories. Although very few 
laboratories in Taiwanese hospitals routinely perform 
MHT to screen for KPCs, there are no reports till now 
to document the presence any KPCs in Enterobacteriaceae 
isolates in Taiwan. Finally, several laboratories in Taiwan 
use automated instruments, including Vitek II (bio-
Mérieux Vitek, Marcy l’Etoile, France) or Phoenix (Becton 
Dickinson, Sparks, MD, USA), for susceptibility testing of 
Enterobacteriaceae isolates. The MIC ranges of some anti-
microbial agents tested in the antibiotic panels of these 
instruments (cefazolin and ertapenem in Phoenix and 
Vitek II; ceftriaxone in Phoenix) are not able to detect sus-
ceptible or intermediate isolates when using the new in-
terpretive breakpoints (Tables 2 and 3).1–3
The consensus meeting concluded that owing to some 
subgroups of ESBL-producing isolates that remained 
susceptible to ceftazidime and cefepime defined by the 
CLSI 2010 breakpoints, confirmation testing of ESBL 
phenotypes may still be helpful in monitoring evolving 
epidemiology and to assist in early implementation of 
appropriate infection control measures. This situation 
is especially important in countries (e.g. Taiwan) with a 
high burden of infections caused by ESBL-producing 
Enterobacteriaceae. The decreased susceptibility to ertapenem 
of some Enterobacteriaceae isolates using the new criteria is 
alarming, particularly for ESBL-producing K. pneumoniae 
and E. cloacae. There is an urgent need to establish the 
local microbiological and clinical outcome data to sup-
port the necessity of implementing these new criteria in 
Taiwanese clinical microbiology laboratories and in clini-
cal practice to ensure appropriate antimicrobial therapy 
in the management of infections due to Enterobacteriaceae.
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